Daxor to Showcase Next-Gen Blood Volume Analyzer and New Clinical Data at HFSA 2026

Daxor Corporation (DXR) will showcase its FDA-cleared next-gen Blood Volume Analyzer (BVA) at HFSA 2026, featuring 3x faster results and 50% less blood required. Clinical data on heart failure management will be presented, highlighting BVA's accuracy and efficiency. The event runs Oct 9-12, 2026, in Phoenix, AZ.

Original reporting
Published Oct 1, 2026, 12:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 1, 2026, 12:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$DXR
Neutral
high confidence
Mentioned
$DXR
Relevance
4/10
AlphAI data visualization · based on globenewswire.com
Decision brief

The 30-second read

$DXRNeutralLow
01

Why it matters

The announcement is a standard corporate PR piece; no new financial metrics, contracts, or regulatory outcomes are disclosed beyond the existing FDA clearance.

02

Market read

Limited short‑term relevance; primarily a product awareness effort with potential long‑term sales implications.

03

What to watch

Potential competitive response from larger diagnostics firms and reimbursement uncertainties could affect long‑term adoption.

Relevance 4/10Novelty 3/10Timing: during HFSA event Oct 9‑12 2026

Background

Daxor (NASDAQ:DXR) specializes in blood‑volume measurement technology. The company’s next‑gen analyzer claims 3× faster results and 50% less blood draw, aiming at heart‑failure management markets.

Company-level read

Ticker impact

$DXRNeutralHigh confidence
Context

Daxor announced it will exhibit its FDA‑cleared next‑generation Blood Volume Analyzer at the HFSA 2026 meeting, highlighting new clinical data and faster, lower‑volume testing.

Expected impact

likely limited pressure as investors await commercial uptake data; no near‑term catalyst.

Evidence & confidence

Press releases of new devices without revenue guidance or contract values typically generate only modest short‑term price movement.

Market effects

May raise awareness of blood‑volume diagnostics within the heart‑failure device sector, but no sector‑wide shift expected.

Limited to U.S. and possibly European hospital markets where Daxor sells its devices.

Low; product relevance is niche and early‑stage.

Counterpoint

Investors could view the announcement as a distraction without concrete sales traction, keeping the stock flat.

Key entities

  • Daxor Corporation

    US‑listed medical device maker (NASDAQ:DXR) focusing on blood‑volume analysis.

  • Heart Failure Society of America (HFSA)

    Venue for the product showcase and clinical data presentations.

Related articles

$DXRMedAI 8/10

Daxor presents clinical data on blood volume analysis technology

Daxor Corporation (DXR) presented clinical data at the Heart Failure Society of America 2026 Annual Scientific Meeting, showing its blood volume analysis (BVA) technology improved patient outcomes in heart failure studies. The BVA system, FDA-cleared with over 95% accuracy, identified fluid issues and guided treatment. The company has operated for 50 years and holds ISO certification.

$DXRMedAI 8/10

Daxor Corporation Receives U.S. Patent for Breakthrough Remote Blood Volume Monitor

Daxor Corporation (Nasdaq: DXR) said the USPTO issued U.S. Patent No. 12,635,917 B2 for a “Remote Blood Volume Monitor.” The patent covers systems for continuous, remote tracking of absolute blood volume after a baseline test by combining Daxor blood-volume algorithms with subsequent hematocrit monitoring, including non-invasive wearable optical sensors (e.g., PPG). Daxor said it targets conditions such as heart failure, syncope, anemia, and polycythemia.

$NNVCMed

NanoViricides, Inc. Has Filed its Quarterly Report - Broad-Spectrum Antiviral Drug NV-387 Oral Gummies Has Entered Two Separate Phase II Clinical Trials - One to Treat Ebola Bundibugyo Virus Disease, and Another to Treat Mpox

NanoViricides, Inc. (NYSE American:NNVC) filed its Q3 2026 report, revealing Phase II trials for NV-387 Oral Gummies to treat Ebola and Mpox. The company has $2.98M in cash and $9.56M in total assets, but warns of insufficient funding for operations beyond November 2027.

$UBERMed

Kohl’s products now available for delivery on Uber Eats

Uber (UBER) and Kohl's (KSS) partnered to offer Kohl's products via Uber Eats, covering 1,100+ U.S. stores. Items include apparel, home goods, and Sephora beauty products. The service launches before the holiday season, with a $10 discount on first orders over $50 until December 3, 2026. Kohl's operates 1,100+ stores in 49 states.

$SPCBMed

SuperCom Wins 2nd Electronic Monitoring Contract in Indiana, Fully Displacing Incumbent Provider

SuperCom (SPCB) won its second electronic monitoring contract in Indiana, replacing an incumbent provider. The deal involves deploying its PureSecurity suite, with rollout starting in December 2026. The company reported a trailing twelve-month EBITDA of approximately $12.1 million through Q3 2026, citing over 50 new U.S. contracts and 20 national project wins in Europe since mid-2024.